Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;34(3):185-190.
doi: 10.1007/s40290-020-00332-1.

Establishing Patient Registries for Rare Diseases: Rationale and Challenges

Affiliations
Review

Establishing Patient Registries for Rare Diseases: Rationale and Challenges

Vanessa Boulanger et al. Pharmaceut Med. 2020 Jun.

Abstract

Globally, an estimated 350 million people are affected by a rare disease diagnosis. Knowledge limitations persist for the majority of rare conditions due to systemic and structural challenges in healthcare and research. Disease-specific patient populations are often small and geographically dispersed; funding support for research is restricted; and diagnostic delays are common due to disease complexities, limited medical training for practitioners, and evolving foundational knowledge related to disease characterization. Patient registries can be effective, convenient, and cost-efficient tools to support documentation of the natural history of a disease, centering patients as research partners in the process while uniting rare communities around a common initiative. Current global trends towards innovative and patient-centered healthcare are enabling patient registries to increasingly emerge as valuable tools for use within rare disease research and drug development. This article describes the value of and rationale for establishing rare disease patient registries and the considerations and challenges that stakeholders, such as researchers, industry, health care providers, and patient community organizations, may encounter.

PubMed Disclaimer

Conflict of interest statement

The authors are employed by the National Organization for Rare Disorders and are responsible for oversight of the IAMRARE™ Patient Registry Program. Authors are also partners in the Rare Disease Cures Accelerator [40].

References

    1. Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Lipkin G, Calvert M. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61. doi: 10.1186/s13023-018-0810-x. - DOI - PMC - PubMed
    1. Groft SC. Rare diseases research: expanding collaborative translational research opportunities. Chest. 2013;144(1):16–23. doi: 10.1378/chest.13-0606. - DOI - PMC - PubMed
    1. GARD. FAQS about rare diseases. 2017. https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rarediseases. Accessed 20 Feb 2020.
    1. Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA, International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Groups Rare disease terminology and definitions—a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18:906–914. doi: 10.1016/j.jval.2015.05.008. - DOI - PubMed
    1. Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases—the view from the National Center for Advancing Translational Sciences—Office of Rare Diseases Research. Orphanet J Rare Dis. 2018;13(1):196. doi: 10.1186/s13023-018-0936-x. - DOI - PMC - PubMed

Publication types